In this issue:
- AI-detected TILs and outcomes for anti-PD-1-treated melanoma
- Skin cancers among renal transplant recipients from Canterbury
- Adjuvant nivolumab-relatlimab for stage III–IV melanoma
- Decreased naevus counts and improved sun behaviours among Australian children
- Long-term adjuvant anti-PD-1 or targeted therapy in realworld stage III melanoma
- Ambient UVB and UVA, and keratinocyte carcinoma incidence in the US
- BO-112 + pembrolizumab for anti-PD-1-resistant advanced melanoma
- Assessment of misdiagnosed SCCs
- Response-adapted surgical and RT de-escalation in resectable SCC using pembrolizumab
- RT vs. imiquimod for complex lentigo maligna
Please login below to download this issue (PDF)